Bessemer Group Inc. Sells 700 Shares of Atrion Co. (ATRI)

Bessemer Group Inc. lowered its holdings in Atrion Co. (NASDAQ:ATRI) by 29.2% in the 4th quarter, HoldingsChannel reports. The firm owned 1,700 shares of the medical instruments supplier’s stock after selling 700 shares during the quarter. Bessemer Group Inc.’s holdings in Atrion were worth $1,072,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ATRI. Dimensional Fund Advisors LP grew its position in shares of Atrion by 1.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 64,290 shares of the medical instruments supplier’s stock worth $43,203,000 after buying an additional 1,022 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Atrion by 145.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,057 shares of the medical instruments supplier’s stock worth $2,732,000 after buying an additional 2,402 shares during the last quarter. OxFORD Asset Management LLP grew its position in shares of Atrion by 15.6% in the 3rd quarter. OxFORD Asset Management LLP now owns 1,941 shares of the medical instruments supplier’s stock worth $1,313,000 after buying an additional 262 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Atrion by 600.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,383 shares of the medical instruments supplier’s stock worth $2,177,000 after buying an additional 2,900 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Atrion by 31.9% in the 2nd quarter. Wells Fargo & Company MN now owns 2,160 shares of the medical instruments supplier’s stock worth $1,390,000 after buying an additional 523 shares during the last quarter. Institutional investors and hedge funds own 59.09% of the company’s stock.

Atrion Co. (NASDAQ:ATRI) opened at $543.50 on Friday. Atrion Co. has a 12-month low of $459.05 and a 12-month high of $694.00. The stock has a market cap of $1,020.00, a P/E ratio of 30.11 and a beta of 0.73.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings data on Wednesday, November 8th. The medical instruments supplier reported $4.29 earnings per share (EPS) for the quarter. Atrion had a net margin of 22.98% and a return on equity of 18.34%. The firm had revenue of $37.90 million for the quarter.

Separately, BidaskClub downgraded shares of Atrion from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th.

COPYRIGHT VIOLATION NOTICE: “Bessemer Group Inc. Sells 700 Shares of Atrion Co. (ATRI)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/02/09/bessemer-group-inc-sells-700-shares-of-atrion-co-atri.html.

About Atrion

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Want to see what other hedge funds are holding ATRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atrion Co. (NASDAQ:ATRI).

Institutional Ownership by Quarter for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit